Pathway analysis in Fig. 6a also indicates that TAMs from ASH1L-depleted bone tumors exhibited decreased IGF downstream signaling, i.e., AKT and MAPK pathways, suggesting IGF signaling may be involved in the TAM plasticity and metabolic programming driven by ASH1L. The gene discussed is AKT1; the disease is bone neoplasm.